3
Announcements
Trials
Browse
Landscape
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Myeloproliferative Disorders
2
Multiple Myeloma
2
Leukemia, Myeloid, Acute
2
Venous Thromboembolism
1
Thrombophilia
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Sleep Apnea, Obstructive
1
Sezary Syndrome
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Neuroblastoma
1
Neoplasms
1
Myeloproliferative Syndrome, Transient
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukopenia
1
Leukemia, Neutrophilic, Chronic
1
Leukemia, Myelomonocytic, Chronic
1
Interventions
luspatercept
4
Biopsy
4
Lenalidomide
3
Epoetin Alfa
3
Cyclophosphamide
3
Busulfan
3
ruxolitinib
2
fludarabine
2
Filgrastim
2
Cyclosporine
2
Antilymphocyte Serum
2
AP 1903 reagent
2
ACE-011
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
venetoclax
1
vactosertib
1
trametinib
1
thymoglobulin
1
siltuximab
1
regorafenib
1
ponatinib
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
olaparib
1
neratinib
1
lorlatinib
1
lenvatinib
1
idelalisib
1
fludarabine phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anemia
×
Observation
×
Myeloid
×
Clear all
NCT07108023
2025-08-06
EHPVO-HEM
Assiut University
Not yet recruiting
115 enrolled